BCL2 and type 1 diabetes mellitus: Bcl-2 inhibitors reduced the level of islet inflammation by selectively eliminating senescent β cells with high Bcl-2 expression, thereby preventing or delaying the onset of T1DM (Thompson et al., 2019).